+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Nocturia - Pipeline Insight, 2021

  • ID: 4037287
  • Drug Pipelines
  • May 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • Ferring Pharmaceuticals
  • Kao Corporation
  • Sanwa Kagaku Kenkyusho
  • Tacurion Pharma
  • Vantia Therapeutics
  • MORE
This Nocturia - Pipeline Insight, 2021 report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Nocturia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Nocturia Understanding

Nocturia: Overview

Nocturia is a condition that causes you to wake up during the night to urinate. This can be thought of as nocturnal urinary frequency - having to urinate more often at night. This condition becomes more common as people age and occurs in both men and women. Nocturia can be caused by: Polyuria: when a body makes too much urine in a 24-hour period, Nocturnal polyuria: when a body makes too much urine during the night, Bladder storage problems: when a bladder doesn't store or release urine well. Mixed nocturia: when more than one of these problems are happening. Nocturia can have significant health consequences. It may be connected to serious underlying problems, and nighttime bathroom trips can both disrupt sleep and create additional health concerns. Anticholinergic medications (these can reduce symptoms of an overactive bladder), Bumetanide (Bumex®), Furosemide (Lasix®) (diuretics that assist in regulating urine production), Desmopressin (DDAVP®) (helps the kidneys produce less urine) might be helpful in treating the condition.

Nocturia - Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Nocturia pipeline landscape is provided which includes the disease overview and Nocturia treatment guidelines. The assessment part of the report embraces, in depth Nocturia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nocturia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Nocturia R&D. The therapies under development are focused on novel approaches to treat/improve Nocturia.

Nocturia Emerging Drugs Chapters

This segment of the Nocturia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Nocturia Emerging Drugs

Fedovapagon: Vantia Therapeutics

Vantia Therapeutics is developing fedovapagon, an orally administered, small-molecule vasopressin V2 agonist, for the treatment of Nocturia. Vantia Therapeutics reported positive top-line data from a pivotal Phase III trial investigating the efficacy and safety of fedovapagon (VA106483) in the treatment of nocturia in men with benign prostatic hyperplasia.

FE 201836: Ferring Pharmaceuticals

An oral solution of FE 201836 for treatment of nocturia is being developed by Ferring Pharmaceuticals. Clinical developments are underway in U.S for treatment of Nocturia.

Nocturia: Therapeutic Assessment

This segment of the report provides insights about the different Nocturia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Nocturia

There are approx. 5+ key companies which are developing the therapies for Nocturia. The companies which have their Nocturia drug candidates in the most advanced stage, i.e. Phase II/III include, Vanita Therapeutics.

Phases

This report covers around 5+ products under different phases of clinical development like
  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Nocturia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Nocturia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nocturia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nocturia drugs.

Nocturia Report Insights
  • Nocturia Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Nocturia Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Nocturia drugs?
  • How many Nocturia drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nocturia?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nocturia therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Nocturia and their status?
  • What are the key designations that have been granted to the emerging drugs?


This report will be delivered within 2 business days.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Ferring Pharmaceuticals
  • Kao Corporation
  • Sanwa Kagaku Kenkyusho
  • Tacurion Pharma
  • Vantia Therapeutics
  • MORE
Introduction

Executive Summary

Nocturia: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Nocturia - Analytical Perspective

In-depth Commercial Assessment
  • Nocturia companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Nocturia Collaboration Deals
  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase II/III)
  • Comparative Analysis
Fedovapagon: Vantia Therapeutics
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
FE 201836: Ferring Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Early stage products (Phase I)
  • Comparative Analysis
USRP 003: Kao Corporation
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Nocturia Key Companies

Nocturia Key Products

Nocturia- Unmet Needs

Nocturia- Market Drivers and Barriers

Nocturia- Future Perspectives and Conclusion

Nocturia Analyst Views

Nocturia Key Companies

Appendix

List of Tables
Table 1 Total Products for Nocturia
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Nocturia
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown
  • Tacurion Pharma
  • Ferring Pharmaceuticals
  • Kao Corporation
  • Vantia Therapeutics
  • Sanwa Kagaku Kenkyusho
Note: Product cover images may vary from those shown
Adroll
adroll